IRVINE, Calif., March 23, 2022 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter and year ended December 31, 2021 and provided a business update. 2021 Highlights Raised gross proceeds of… Continue reading Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
